Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -89.18% is 13% below its 5-year average of -79.13%, around the middle of its 5-year range (-136.24%–-35.73%).
10.95% above its 12-month average of -100.15%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.41%.
RETURN ON ASSETS (ROA)
-89.18%
RETURN ON ASSETS (ROA) AVG TTM
-100.15%
RETURN ON ASSETS (ROA) AVG 3Y
-92.96%
RETURN ON ASSETS (ROA) AVG 5Y
-79.13%
RETURN ON ASSETS (ROA) AVG 10Y
-59.71%
RETURN ON ASSETS (ROA) AVG 15Y
-48.39%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.95%
CURRENT VS 3Y AVG
+4.07%
CURRENT VS 5Y AVG
-12.70%
CURRENT VS 10Y AVG
-49.37%
CURRENT VS 15Y AVG
-84.29%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-25.07%
median of 452 covered companies
CURRENT VS SECTOR MEDIAN
-255.79%
vs the sector median at left
Crescent Biopharma, Inc.
Market Cap
$517.79M
Return on Assets (ROA)
-89.18%
TTM Avg
-100.15%
3Y Avg
-92.96%
5Y Avg
-79.13%
Market Cap
$517.73M
Return on Assets (ROA)
-30.08%
TTM Avg
-46.42%
3Y Avg
-46.30%
5Y Avg
-37.15%
Market Cap
$519.25M
Return on Assets (ROA)
-17.40%
TTM Avg
-49.85%
3Y Avg
-45.66%
5Y Avg
-41.17%
Market Cap
$491.93M
Return on Assets (ROA)
-13.84%
TTM Avg
-22.27%
3Y Avg
-29.75%
5Y Avg
-35.86%
Market Cap
$491.55M
Return on Assets (ROA)
-3.84%
TTM Avg
-6.38%
3Y Avg
-6.57%
5Y Avg
-4.38%
Market Cap
$547.86M
Return on Assets (ROA)
0.39%
TTM Avg
-16.14%
3Y Avg
-90.03%
5Y Avg
-84.55%
Market Cap
$487.30M
Return on Assets (ROA)
-8.14%
TTM Avg
-30.20%
3Y Avg
-72.84%
5Y Avg
-64.85%
Market Cap
$551.09M
Return on Assets (ROA)
-16.69%
TTM Avg
-61.13%
3Y Avg
-63.72%
5Y Avg
-100.27%
Market Cap
$481.33M
Return on Assets (ROA)
1.38%
TTM Avg
-14.74%
3Y Avg
-19.98%
5Y Avg
-18.10%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | $517.79M | -89.18% | -100.15% | -92.96% | -79.13% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | -30.08% | -46.42% | -46.30% | -37.15% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -17.40% | -49.85% | -45.66% | -41.17% |
| Evolus, Inc. (EOLS)vs › | $491.93M | -13.84% | -22.27% | -29.75% | -35.86% |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | -3.84% | -6.38% | -6.57% | -4.38% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 0.39% | -16.14% | -90.03% | -84.55% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | -8.14% | -30.20% | -72.84% | -64.85% |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | -16.69% | -61.13% | -63.72% | -100.27% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | 1.38% | -14.74% | -19.98% | -18.10% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -22.99% | -20.77% | -18.00% | -22.63% |
ROA
-89.2%
ROE
-99.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -64.06% |
| 2024-12-31 | -136.24% |
| 2023-12-31 | -81.43% |
| 2022-12-31 | -90.11% |
| 2021-12-31 | -67.23% |
| 2020-12-31 | -35.73% |
| 2019-12-31 | -32.22% |
| 2018-12-31 | -22.47% |
| 2017-12-31 | -25.88% |
| 2016-12-31 | -75.04% |
| 2015-12-31 | -26.35% |
| 2014-12-31 | -19.42% |
| 2013-12-31 | -200.73% |
| 2012-12-31 | 19.85% |
| 2011-12-31 | -21.15% |
